Journal article
Epirubicin in Breast Cancer: Present and Future
Abstract
Epirubicin, a member of the anthracycline family of chemotherapeutic agents, has been widely used throughout the world both as adjuvant therapy in early breast cancer and in metastatic breast cancer. Clinical trials with epirubicin have examined the importance of a dose-response relationship, therapeutic dose, and optimum duration of chemotherapy. In addition, pharmacokinetic studies have provided data on ideal combinations with other agents. …
Authors
Levine M
Journal
Clinical Breast Cancer, Vol. 1, , pp. s62–s67
Publisher
Elsevier
Publication Date
September 2000
DOI
10.3816/cbc.2000.s.012
ISSN
1526-8209